This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Methyltrienolone is 17α-alkylated for oral bioavailability — a structural feature directly responsible for the most severe hepatotoxic class of AAS. Cholestatic injury, peliosis hepatis, and hepatic adenoma are all class-documented. Cycle length must be capped (typically < 6-8 weeks); LFTs (ALT, AST, GGT, bilirubin) baseline + every 2 weeks on cycle. Stop immediately on ALT/AST > 3× ULN or symptomatic jaundice.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Methyltrienolone
17α-methylated trenbolone — the oral version of the most potent mainstream injectable AAS, sold via gray-market UGLs and used in lab…
Aliases (6)
Overview
What is Methyltrienolone?
Methyltrienolone (M3, "Metribolone") is an extremely potent oral 17α-methylated nor-19 anabolic-androgenic steroid. It is used in research as a high-affinity AR ligand and rarely in underground bodybuilding.
Key Benefits
Extremely high anabolic and androgenic potency relative to dose, useful as a research probe for the androgen receptor, and historically tested as a breast-cancer therapy; however, hepatotoxicity is severe.
Mechanism of Action
Binds the androgen receptor with very high affinity and very slow off-rate, producing potent and prolonged AR signaling. Cannot aromatize but interacts with progesterone and glucocorticoid receptors. The 17α-methyl group drives marked hepatotoxicity.
Pharmacokinetics
▸ Cycle structure & PCT AAS oral
Ramp dose over week 1, hold steady through cycle weeks. Track baseline labs (TT/FT/E2/SHBG/HCT/lipids/LFTs) at week 0; recheck at week 4 and end-of-cycle.
On the last dose, the ester clears over its half-life window (enanthate = est. 7 days). PCT begins after the active compound has cleared.
Standard PCT is enclomiphene 12.5-25 mg/day or clomid 50/50/25/25 over 4 weeks (or nolvadex 20/20/10/10). HCG bridge optional during cycle to preserve testicular volume + faster restart. Bloodwork at PCT week 4 + 8 to confirm HPG axis recovery (LH, FSH, TT back to baseline).
Research Indications
Glucocorticoid receptor (GR) agonist
drives anxiety, sleep destruction, cardiovascular damage, connective-tissue catabolism (the "tren-class" subjective profile).
Progestogenic activity
prolactin elevation, gynecomastia risk that aromatase inhibitors don't address.
Non-aromatizing
does not convert to estradiol, removing estrogen's cardioprotective effects (HDL crash, vascular endothelial damage).
5α-reductase resistant
does not convert to DHT but is itself extraordinarily androgenic.
HPG suppression: among the most severe of any AAS
LH/FSH crash within days; recovery post-cycle slow and uncertain.
Peptide Interactions
hepatotoxicity additive and often catastrophic.
stacks tren-class CV/HPG damage non-linearly.
additive cardiovascular load.
additive hepatic stress (n/a for users in this archetype but noted for class context).
additive hepatic + renal stress.
unpredictable interaction with AAS-mood axis.
additive hepatic stress on a 17α-methyl backbone is particularly poorly tolerated.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Week 1-2Frontload phase. Strength gains start; appetite up.
- Week 3-4Visible muscle fullness and recovery acceleration.
- Week 5-8Peak performance window. Monitor blood pressure + libido.
- Post-cyclePCT week 1-4. Bloodwork at week 6 post-cycle.
Side Effects & Safety
- Common (>10% users): Insomnia, night sweats, severe mood lability, irritability, elevated BP, elevated resting HR, sexual dysfunction (mid-cycle ED), severe HPG suppression (universal at any meaningful dose), ALT/AST elevation within first 1-2 weeks, water retention modest.
- Less common (1-10%): Cholestatic jaundice (yellowing, dark urine, pruritus), gynecomastia (progestogenic — AI does not address), aggression incidents, panic-attack-like episodes, severe acne, accelerated androgenic alopecia, kidney function decline, prostate symptoms.
- Rare-serious (<1% but worth knowing):
- Peliosis hepatis — blood-filled cystic lesions in the liver that can rupture catastrophically. 17α-methyl AAS are the primary pharmacologic cause; methyltrienolone is among the highest-risk in the class given its potency.
- Hepatic adenoma / hepatocellular carcinoma — documented with prolonged 17α-methyl AAS use; methyltrienolone's potency means meaningful exposure happens at lower mg-doses than other 17α-AAS.
- Acute liver failure — case reports exist for the 17α-methyl class with cholestatic liver failure progressing to ICU admission.
- Cardiac event (MI, arrhythmia, cardiomyopathy) — HDL crash + hypertension + erythrocytosis + GR activation stack acutely on-cycle.
- Acute kidney injury — case reports in the 19-nor / tren-class.
- Psychotic episode, manic episode, suicidal ideation — vulnerable users.
- Persistent post-cycle hypogonadism — failure to recover endogenous T after even short methyltrienolone exposures, given tren-class HPG suppression severity.
- Tren cough analog — some users report acute respiratory reactions, though injection-route tren cough is not directly applicable to oral mtren.
- Specific watch periods:
- First 7 days: liver enzymes (ALT/AST/GGT/bilirubin) — methyltrienolone hits hepatic injury thresholds fastest of any commonly-discussed AAS.
- Any RUQ pain, jaundice, dark urine, pruritus, or unexplained fatigue is an emergency stop.
- First 4 weeks: psychiatric side effects peak (sleep, mood).
- Mid-cycle through PCT: lipid panel, cardiac surveillance, kidney function.
- 6-12 months post-cycle: ASIH may persist; some users never recover.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.